Middle East Pharmaceutical Industries Co. announces signing of a Memorandum of Understanding with Aurisco Pharma for Strategic Cooperation on Oligonucleotide and Other Complex Pharmaceutical Products
| Element List | Explanation |
|---|---|
| Introduction | Middle East Pharmaceutical Industries Co. (Avalon Pharma) announces the signing of a Memorandum of Understanding (MoU) with Aurisco Pharma for strategic cooperation on oligonucleotide and other complex pharmaceutical products, opening the door to a new generation of medicines that act at the RNA level. Starting with Inclisiran as the initial identified project, the cooperation is intended to lay the foundation for a broader platform of potential additional products and technologies, including development, technology transfer and local manufacturing in the Kingdom of Saudi Arabia. For Avalon, the MoU marks a strategic step towards a future-facing position in one of the most promising frontiers of pharmaceuticals, bringing advanced therapies closer to patients in the region. |
| Memorandum Signing Date | 2026-10-06 Corresponding to 1448-04-25 |
| Counterparty | Aurisco Pharma, a company incorporated under the laws of the People’s Republic of China, with expertise in oligonucleotide API manufacturing, formulation process development, analytical method development and technical transfer |
| Memorandum Subject | Strategic Cooperation on Oligonucleotide and Other Complex Pharmaceutical Products |
| Memorandum Duration | Six months from the Effective Date for the parties to agree on a project cooperation term sheet |
| Related Parties | There are no related parties involved in this transaction. |
| Financial Impact | No contract value has been determined at this stage. Commercial and financial terms will be negotiated and documented in subsequent definitive agreements. |
| Additional Information | The partnership strengthens Avalon’s complex injectable portfolio and supports localization of manufacturing in the Kingdom of Saudi Arabia, in line with Vision 2030. Oligonucleotides are a high-value, fast-evolving category with significant long-term potential, and the MoU positions Avalon to build capabilities in it, starting with Inclisiran as the first project and moving towards a broader portfolio of oligonucleotide and complex products, with local manufacturing in Riyadh. |
Comments